DexCom (DXCM)
(Delayed Data from NSDQ)
$69.00 USD
-0.70 (-1.00%)
Updated Nov 5, 2024 04:00 PM ET
After-Market: $68.91 -0.09 (-0.13%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth A Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$69.00 USD
-0.70 (-1.00%)
Updated Nov 5, 2024 04:00 PM ET
After-Market: $68.91 -0.09 (-0.13%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth A Momentum B VGM
Zacks News
Here's Why Investors Should Retain Labcorp (LH) Stock for Now
by Zacks Equity Research
Investors are increasingly optimistic about Labcorp (LH) due to development in targeted high-growth areas.
Orthofix (OFIX) Q3 Earnings Top Estimates, 2023 Sales View Cut
by Zacks Equity Research
Orthofix (OFIX) saw very strong growth across multiple business segments and product lines in Q3.
Labcorp (LH) Closes the Legacy Health Asset Acquisition Deal
by Zacks Equity Research
Labcorp (LH) finalizes the comprehensive laboratory relationship with Legacy Health.
Cardinal Health (CAH) Hits 52-Week High: What's Aiding It?
by Zacks Equity Research
Investors are optimistic about Cardinal Health's (CAH) diversified product portfolio.
EssilorLuxottica (ESLOY), Moncler Ink Luxury Eyewear Deal
by Zacks Equity Research
The first Moncler Lunettes collection produced with EssilorLuxottica (ESLOY) is called Fall-Winter 2024.
Here's Why You Should Retain Edward Lifesciences (EW) Stock Now
by Zacks Equity Research
Investors remain optimistic about Edward Lifesciences (EW) due to Surgical's differentiated portfolio and TMTT franchise.
Quest Diagnostics' (DGX) New Pact to Advance Cancer Screening
by Zacks Equity Research
Quest Diagnostics' (DGX) latest partnership will increase the likelihood that Americans will eventually have an easy, reliable and accessible way to check for colorectal cancer.
Abbott (ABT) Benefits From Innovation Amid FX Headwinds
by Zacks Equity Research
Abbott's (ABT) mAbxience collaboration is likely to help introduce cutting-edge medicines in the areas of oncology, women's health and respiratory diseases.
Teleflex (TFX) Enrolls First Patient in ACCESS-MANTA Registry
by Zacks Equity Research
Teleflex's (TFX) ACCESS-MANTA Registry is likely to examine the contemporary on-label use of the MANTA VCD.
Medtronic (MDT) Q2 Earnings Beat Estimates, 2024 View Up
by Zacks Equity Research
Medtronic (MDT) Q2 results reflect broad strength across businesses and geographies, benefiting from durable fundamentals.
Here's Why You Should Retain Myriad Genetics (MYGN) Stock Now
by Zacks Equity Research
Investors are optimistic about Myriad Genetics (MYGN) on recent partnerships and growth in testing volumes.
Zimmer Biomet's (ZBH) Knee Sales Robust, Macro Woes Hurt
by Zacks Equity Research
Zimmer Biomet (ZBH) is working to strengthen its foothold in emerging markets that provide long-term opportunities for growth.
Boston Scientific (BSX) Closes the Relievant Medsystems Buyout
by Zacks Equity Research
Boston Scientific (BSX) expands the neuromodulation portfolio with the acquisition of Relievant Medsystems.
Here's Why Investors Should Retain STERIS (STE) Stock for Now
by Zacks Equity Research
STERIS' (STE) Healthcare segment continues to benefit from procedure volume recovery.
DexCom (DXCM) is an Incredible Growth Stock: 3 Reasons Why
by Zacks Equity Research
DexCom (DXCM) is well positioned to outperform the market, as it exhibits above-average growth in financials.
National Vision's (EYE) Market Expansion Aids, Inflation Ails
by Zacks Equity Research
National Vision (EYE) is expanding sales by the continued rollout of its remote medicine technology.
Myriad Genetics (MYGN) Expands Pharma Services With New Pact
by Zacks Equity Research
Myriad Genetics (MYGN) will market the Personalis ImmunoID NeXT ultra-comprehensive biomarker discovery platform to its pharmaceutical partners with a new collaboration.
Medtronic's (MDT) Symplicity Spyral RDN System Gets FDA Boost
by Zacks Equity Research
Medtronic (MDT) receives the FDA approval for Symplicity blood pressure procedure for the treatment of hypertension.
Paragon 28 (FNA) BEAST Cortical Fibers Launch Boosts Biologics
by Zacks Equity Research
Paragon 28's (FNA) BEAST Cortical Fibers' advanced processing capability ensures the preservation of native bone morphogenic proteins and other growth factors crucial for bone formation.
Zacks.com featured highlights include DexCom, Arthur J. Gallagher, Limbach and The Hartford Financial Services
by Zacks Equity Research
DexCom, Arthur J. Gallagher, Limbach and The Hartford Financial Services are part of the Zacks Screen of the Week article.
Nemaura (NMRD) to Expand in UK With Metabolic Health Program
by Zacks Equity Research
The latest program leverages Nemaura's (NMRD) world-first daily wear non-invasive CGM technology, providing individuals with real-time insights into their body's glucose dynamics.
What's in the Cards for Medtronic (MDT) in Q2 Earnings?
by Zacks Equity Research
Strength in all four businesses is likely to drive Medtronic's (MDT) fiscal second-quarter performance.
Neogen's (NEOG) Innovation Aids, Currency Headwind Stays
by Zacks Equity Research
Neogen (NEOG) is progressing well in terms of picking the right growth markets and gaining a bigger share of those markets.
Reasons to Add DexCom (DXCM) Stock to Your Portfolio Now
by Zacks Equity Research
DexCom (DXCM) continues to raise optimism among investors, owing to its strong product portfolio.
Charles River (CRL) Widens CliniPrime GMP Suite With New Launch
by Zacks Equity Research
Charles River (CRL) brings CliniPrime Cryopreserved Leukopaks for cell therapy development and manufacturing.